Search Within

Martin Henner Voss

  1. "2024"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (6)
  3. Editorial (2)
Groups
  1. Department of Medicine (15)
  2. Genitourinary Oncology Service (15)
  3. Solid Tumor Oncology Division (15)
  4. Weinberg Fellows (9)
  5. Graduate Medical Education (8)
  6. Hematologic Malignancies, Division of (8)

More Groups

People
  1. Robert Motzer (11)
  2. Ritesh Kotecha (8)
  3. Andrea Knezevic (6)
  4. Chung-Han Lee (6)
  5. Maria Carlo (6)
  6. Darren Feldman (5)

More People

Years
  1. 2024 (15)
Publications
  1. Journal of Clinical Oncology (6)
  2. European Urology (2)
  3. Urologic Oncology: Seminars and Original Investigations (2)
  4. BMJ Oncology (1)
  5. Cancer (1)
  6. European Urology Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. Elsevier Inc. (2)
  3. Elsevier Science, Inc. (2)
  4. BMJ Publishing Group Ltd (1)
  5. Biomed Central Ltd (1)
  6. Elsevier BV (1)

More Publishers

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management of kidney cancer relapse to adjuvant pembrolizumab: Early insights and questions for a newly emerging space
    Editorial

    Voss, M. H.; Motzer, R. J.
    European Urology (2024)

    Fulltext@MSK | Save
  • Real world data on treatment of chromophobe renal cell carcinoma
    Meeting Abstract

    Battle, D.; Griffith, M.; Msaouel, P.; Voss, M. H.; Staehler, M. D.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma
    Meeting Abstract

    Doshi, S. D.; Kuo, F.; Knezevic, A.; Kotecha, R. R.; Motzer, R. J.; Hakimi, A. A.; Voss, M. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study
    Meeting Abstract

    Voss, M. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma
    Meeting Abstract

    Doshi, S. D.; Dizman, N.; Knezevic, A.; Touma, A.; Alaghehbandan, R.; Ged, Y.; Ornstein, M. C.; Hahn, A. W.; Msaouel, P.; Voss, M. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB)
    Meeting Abstract

    Badri, A.; Guercio, B. J.; Ratna, N.; Gavrilov, D.; Metzker, N.; Duzgol, C.; Teo, M. Y.; Regazzi, A. M.; Supplice, L.; Funt, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma
    Meeting Abstract

    Kotecha, R. R.; Doshi, S. D.; Knezevic, A.; Jacobi, R.; Aggen, D. H.; McHugh, D. J.; Shah, N. J.; Carlo, M. I.; Keegan, N. M.; Gayadin, Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Cabozantinib plus nivolumab in patients with non–clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Journal Article

    Fitzgerald, K. N.; Lee, C. H.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y.; Lefkowitz, R. A.; Shah, N. J.; Owens, C. N.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
    Journal Article

    Mantia, C. M.; Jegede, O. A.; Plimack, E. R.; Powles, T.; Motzer, R. J.; Tannir, N. M.; Lee, C. H.; Tomita, Y.; Voss, M. H.; Choueiri, T. K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer
    Journal Article

    Kotecha, R. R.; Doshi, S. D.; Knezevic, A.; Chaim, J.; Chen, Y.; Jacobi, R.; Zucker, M.; Reznik, E.; McHugh, D.; Shah, N. J.; more...
    European Urology Oncology (2024)

    Fulltext@MSK | Save